Patents by Inventor Huanchun CUI

Huanchun CUI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LOW-VISCOSITY, HIGH CONCENTRATION EVOLOCUMAB FORMULATIONS AND METHODS OF MAKING THE SAME
    Publication number: 20230226177
    Abstract: Provided herein are formulations of PCSK9-binding polypeptides, such as those comprising evolocumab, that comprise N-acetyl arginine and have reduced viscosities when compared to formulations lacking N-acetyl arginine. Provided herein are also methods of formulating such compositions that are advantageous in that they conserve certain components. Such formulations comprising PCSK9-binding polypeptides can be administered to patients to treat and/or prevent PCSK9-related diseases, conditions, and disorders.
    Type: Application
    Filed: August 23, 2022
    Publication date: July 20, 2023
    Inventors: Christopher James SLOEY, Sekhar KANAPURAM, Huanchun CUI, Chio Mui CHAN, Elaheh BINABAJI
  • Low-viscosity, high concentration evolocumab formulations and methods of making the same
    Patent number: 11464857
    Abstract: Provided herein are formulations of PCSK9-binding polypeptides, such as those comprising evolocumab, that comprise N-acetyl arginine and have reduced viscosities when compared to formulations lacking N-acetyl arginine. Provided herein are also methods of formulating such compositions that are advantageous in that they conserve certain components. Such formulations comprising PCSK9-binding polypeptides can be administered to patients to treat and/or prevent PCSK9-related diseases, conditions, and disorders.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: October 11, 2022
    Assignee: AMGEN INC.
    Inventors: Christopher James Sloey, Sekhar Kanapuram, Huanchun Cui, Chio Mui Chan, Elaheh Binabaji
  • METHODS FOR REDUCING THE OXIDATION LEVEL OF CYSTEINE RESIDUES IN A SECRETED RECOMBINANTLY-EXPRESSED PROTEIN DURING CELL CULTURE
    Publication number: 20220251502
    Abstract: The present disclosure relates to methods for reducing the oxidation level of cysteine residues in recombinant polypeptides such as anti-IL-17 antibodies during cell culture (e.g., a preparation of secukinumab antibodies) that have been recombinantly produced by mammalian cells. Also provided are purified preparations of recombinant polypeptides such as anti-IL-17 antibodies or antigen binding fragments thereof produced by such methods, e.g, purified preparations of secukinumab. Also provided are purified preparations of recombinant polypeptides produced by such methods wherein the level of active recombinant polypeptide in the preparation is high.
    Type: Application
    Filed: December 21, 2021
    Publication date: August 11, 2022
    Inventors: Nuno BUXO CARINHAS, Huanchun CUI, David GARCIA, Mathias GOEBEL, Joseph SHULTZ
  • LOW-VISCOSITY, HIGH CONCENTRATION EVOLOCUMAB FORMULATIONS AND METHODS OF MAKING THE SAME
    Publication number: 20180237501
    Abstract: Provided herein are formulations of PCSK9-binding polypeptides, such as those comprising evolocumab, that comprise N-acetyl arginine and have reduced viscosities when compared to formulations lacking N-acetyl arginine. Provided herein are also methods of formulating such compositions that are advantageous in that they conserve certain components. Such formulations comprising PCSK9-binding polypeptides can be administered to patients to treat and/or prevent PCSK9-related diseases, conditions, and disorders.
    Type: Application
    Filed: February 22, 2018
    Publication date: August 23, 2018
    Applicant: AMGEN INC.
    Inventors: Christopher James SLOEY, Sekhar KANAPURAM, Huanchun CUI, Chio Mui CHAN, Elaheh BINABAJI